SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (3477)12/30/1997 5:56:00 PM
From: Miljenko Zuanic  Read Replies (2) of 6136
 
You read me wrong. Your assumption, if I am correct, was that Merck will push Crix/Sustiva combo and tried to capture back market which they have lost. Sustiva is good RT drug, they can offer higher discount by offering combo with one or two more RT, but the some can do AGPH/Roche (with GILD help) or VRTX/Glaxo. So they are equal in drug performance/marketing strain. Nobody win, nobody lose. AIDS victim will have lower drugs cost because of the higher competition, which is the only positive thing from this race.

mz
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News